logo
  • Home
  • Solution
  • Impact
  • Science
    • Publications
  • About
    • Team and Board
  • News and Events
    • All News
    • All Events
    • All Press Releases
  • Contact

Approved clinical trial application for BioC gel on complex wounds

19 October, 2022
|In News
|By Helene Hartman

The CTA (Clinical Trial Application) has been approved by the Swedish Medical Products Agency (Läkemedelsverket) and the Ethics committee. The study will include patients with large complex wounds and the aim is to show safety and tolerability.

Recent Posts

  • Xinnate granted patent in Japan for TCP-25 formulation. The patent further strengthens the global intellectual property protection of the TCP-25 gel.
  • Xinnate AB har fått patent godkänt i Japan avseende formulering av TCP-25. Patentet är innebär ett ytterligare stärkt globalt immateriellt skydd för TCP-25 gelen.
  • Xinnate announces that recruitment has started and the first patient has been included in the STEP study with TCP-25
  • Xinnate meddelar att rekryteringen har startat och första patienten har blivit inkluderad i STEP-studien med TCP-25
  • First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25

Archives

  • February 2026
  • January 2026
  • December 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • January 2025
  • December 2024
  • September 2024
  • May 2024
  • March 2024
  • February 2024
  • March 2023
  • October 2022
  • September 2022
  • July 2022
  • March 2022
  • August 2021
  • October 2020
  • January 2020
  • Prev
  • Next
© 2026 Xinnate. All rights reserved